Search clinical trials for: CC-4047,

Total 6578 results

Celgene

No longer available

Expanded Access for CC-4047

Multiple Myeloma

United States
Celgene

Terminated

Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

CC-4047 in Treating Patients With Myelofibrosis

Chronic Myeloproliferative Disorders | Secondary Myelofibrosis

United States
SCRI Development Innovations, LLC
Celgene Corporation

Completed

CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas

Pancreatic Cancer

United States
National Cancer Institute (NCI)

Withdrawn

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

Primary Effusion Lymphoma | Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease
Washington University School of Medicine

Completed

CC-4047 (Pomalidomide) for Graft vs. Host Disease

Graft vs Host Disease

United States
M.D. Anderson Cancer Center
Celgene

Completed

Pomalidomide for Myelofibrosis Patients

Polycythemia Vera | Thrombocythemia

United States
Memorial Sloan Kettering Cancer Center
Weill Medical College of Cornell University; State University of New York -... and other collaborators

Active, not recruiting

Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Pomalidomide for Kaposi Sarcoma in People With or Without HIV

Sarcoma, Kaposi | Kaposi Sarcoma

United States
Celgene Corporation

Completed

Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

Japan
Celgene Corporation

Completed

Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)

Prostate Cancer

United States
Celgene

Completed

A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects (DDI)

Healthy | Pharmacology, Clinical

United States
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Anti-cancer DC Cell Vaccination to Treat Solid Tumors

Solid Tumor, Adult | DC

China
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment

Unspecified Adult Solid Tumor, Protocol Specific

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
Celgene

Completed

Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence (RESUME)

Primary Myelofibrosis | MPN-associated Myelofibrosis

United States, Netherlands, France, Australia, Italy, United Kingdom, Canada, Germany, China, Spain, Belgium, Austria, Poland, Sweden, Japan, Russian Federation
Center for Primary Care and Public Health (Unisante)...
Swiss Tropical & Public Health Institute; Ifakara Health Institute; University... and other collaborators

Recruiting

Dynamic CDSA to Manage Sick Children in Tanzania (DYNAMIC-TZ)

Child Health

Tanzania
Yale University
Celgene Corporation

Completed

Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Celgene

Terminated

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease

Systemic Sclerosis | Scleroderma, Systemic | Systemic Scleroderma | Interstitial Lung Disease | Sclerosis, Systemic

United States, Spain, France, Australia, Italy, Switzerland, Germany, Poland, United Kingdom, Russian Federation
University of Arkansas
Celgene

Completed

Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma

Multiple Myeloma

United States
Celgene

Completed

A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects

Healthy

United States
Celgene

Active, not recruiting

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting (POM MM 014)

Multiple Myeloma

United States, Canada, Japan, Puerto Rico
Celgene
Multiple Myeloma Research Consortium

Completed

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
Celgene

Completed

A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia

Myelofibrosis | Myeloid Metaplasia | Myelofibrosis With Myeloid Metaplasia

United States, Italy, United Kingdom, Austria, Spain
University of Ulm

Active, not recruiting

Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF (POMINC)

Primary Myelofibrosis | Secondary Myelofibrosis | Post-PV MF | PMF | SMF | Post-ET MF

Germany
The Cleveland Clinic

Completed

Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study

Hereditary Hemorrhagic Telangiectasia | Idiopathic Vascular Ectasia

United States
Stanford University
Celgene Corporation

Withdrawn

Pomalidomide for Cough in Patients With Idiopathic Pulmonary Fibrosis

Pulmonary Fibrosis

United States
Celgene

Completed

Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma

Multiple Myeloma

Canada, Denmark, Australia, Belgium, France, Germany, Italy, Netherlands, Russian Federation, Spain, Sweden, Switzerland, United Kingdom, Czechia, Greece
Celgene

Active, not recruiting

Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice

Multiple Myeloma

Austria
Celgene

Completed

Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal) (POM Renal)

Multiple Myeloma | Renal Impairment

United States, Canada
Celgene

Completed

A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.

Multiple Myeloma

Belgium, United Kingdom, Italy, Germany, Sweden, Denmark, Norway, Spain
Celgene

Completed

An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice (MIROIR)

Multiple Myeloma

France
Celgene

Completed

Study to Evaluate Pharmacokinetics of Pomalidomide in Hepatically Impaired Males

Clinical Pharmacology, Healthy Volunteer Study

United States
Celgene

Completed

A Phase 1 QT Study in Healthy Male Subjects (QT/QTc)

Clinical Pharmacology, Healthy Volunteer Study

United States
Celgene

Completed

Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease (SCD-001)

Anemia, Sickle Cell

United States
Celgene

Completed

Food Effect and CYP1A2 Induction Study in Healthy Subjects

Healthy Volunteers

United States
Celgene

Completed

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (OPTIMISMM)

Multiple Myeloma

United States, Spain, United Kingdom, Italy, Israel, Portugal, Germany, Turkey, Greece, Ireland, Austria, Norway, Netherlands, Denmark, Poland, France, Russian Federation, Canada, Finland, Japan, Puerto Rico, Sweden
Celgene

Terminated

A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

Carcinoma, Small Cell

United States, Canada
Celgene

Approved for marketing

Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma (PEXIUS)

Multiple Myeloma

United States, Canada
Celgene

Completed

Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

Japan
Celgene Corporation

Completed

MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States, Canada
Cairo University
Mohamed, Ahmed A., M.D.; Sahr Marzouk; Heba Omar; Michael Wahib Wadeed

Completed

Effect of Different Types of Anesthesia on Perioperative Brain Natriuretic Peptide Levels in Parturient Cardiac Patient Undergoing Elective Cesarean Section

General Anesthesia Versus Spinal Anesthesia on BNP Hormone Levels Preoperatively and Postoperatively in Parturient Cardiac Patient Undergoing C.S

Egypt
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia

Recurrent Waldenstrom Macroglobulinemia | Refractory Waldenstrom Macroglobulinemia

United States
Royal Brompton & Harefield NHS Foundation Trust

Completed

DIGITAL-HF - Digital Tools in Heart Failure - a Survey of Patient Usage (DIGITAL-HF) (DIGITAL-HF)

Heart Failure

United Kingdom
Carol Davila University of Medicine and Pharmacy

Recruiting

Perioperative Complications Linked to COVID-19 History in Elective Cardiac Surgery Patients

COVID-19 | Postoperative Complications

Romania
National Cancer Institute (NCI)

Completed

Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

Neurofibromatosis Type 1 | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System Neoplasm | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Visual Pathway Glioma

United States
Celgene

Completed

2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects

Healthy

United States
National Institutes of Health Clinical Center (CC)

Completed

The Early Reversibility of Rocuronium After Different Doses of Neostigmine

Paralysis

United States
National Institutes of Health Clinical Center (CC)

Completed

Functional and Metabolic Imaging Using Magnetic Resonance Imaging and Spectroscopy

Healthy | Nervous System Disease

United States
National Institutes of Health Clinical Center (CC)

Completed

Effect of Ginkgo Biloba on Phenytoin Elimination

Healthy

United States

Search clinical trials for: CC-4047,

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations